

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020
OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____
Commission File Number: 001-36225

KINDRED BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State of incorporation)

46-1160142
(I.R.S. Employer
Identification No.)

1555 Bayshore Highway, Suite 200
Burlingame, California 94010
(Address of principal executive offices) (Zip code)
Registrant's telephone number: (650) 701-7901

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, \$0.0001 par value	KIN	The NASDAQ Stock Market LLC
Preferred Stock Purchase Rights	KIN	The NASDAQ Stock Market LLC

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter time that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Non-accelerated filer

Accelerated filer
Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 5, 2020, Kindred Biosciences, Inc. had outstanding 39,448,813 shares of common stock, \$0.0001 par value.

Kindred Biosciences, Inc.**TABLE OF CONTENTS**

Part No.	Item No.	Description	Page No.
I		<u>FINANCIAL INFORMATION</u>	
	1	Financial Statements	3
		Condensed Consolidated Balance Sheets as of September 30, 2020 (unaudited) and December 31, 2019	3
		Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2020 and 2019	4
		Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019	5
		Notes to Unaudited Condensed Consolidated Financial Statements	6
	2	Management's Discussion and Analysis of Financial Condition and Results of Operations	26
	3	Quantitative and Qualitative Disclosures About Market Risk	38
	4	Controls and Procedures	38
II		<u>OTHER INFORMATION</u>	
	1	Legal Proceedings	39
1A		Risk Factors	39
	2	Unregistered Sales of Equity Securities and Use of Proceeds	39
	3	Defaults Upon Senior Securities	39
	4	Mine Safety Disclosures	39
	5	Other Information	39
	6	Exhibits	40
		Index to Exhibits	40
		Signatures	41

PART I - FINANCIAL INFORMATION**ITEM 1. FINANCIAL STATEMENTS**

Kindred Biosciences, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)

	September 30, 2020 (Unaudited)	December 31, 2019
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 16,614	\$ 15,986
Short-term investments	45,723	55,723
Accounts receivable	739	923
Inventories	386	4,218
Prepaid expenses and other	4,294	2,495
Total current assets	67,756	79,345
Property and equipment, net	28,593	29,777
Long-term investments	4,500	1,837
Operating lease right-of-use assets	3,634	3,001
Other assets	56	64
Total assets	\$ 104,539	\$ 114,024
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 347	\$ 1,256
Accrued compensation	2,162	4,193
Accrued liabilities	2,011	4,131
Current portion of operating lease liabilities	811	644
Total current liabilities	5,331	10,224
Long-term liabilities:		
Long-term operating lease liabilities	3,147	2,614
Long-term loan payable, net of debt issuance costs	19,524	19,265
Total liabilities	28,002	32,103
Commitments and contingencies (Note 10)		
Stockholders' equity:		
Common stock, \$0.0001 par value; 100,000,000 shares authorized; 39,372,094 and 39,203,533 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	4	4
Additional paid-in capital	310,466	304,963
Accumulated other comprehensive income	24	13
Accumulated deficit	(233,957)	(223,059)
Total stockholders' equity	76,537	81,921
Total liabilities and stockholders' equity	\$ 104,539	\$ 114,024

The accompanying notes are an integral part of these condensed consolidated financial statements.

Kindred Biosciences, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)

	Three months ended September 30,		Nine months ended September 30,	
	2020	2019	2020	2019
Revenues:				
Net product revenues	\$ 16	\$ 1,104	\$ 782	\$ 2,855
Revenue from asset sale	—	—	38,700	—
Partner royalty revenue	255	—	413	—
Contract manufacturing revenue	772	—	1,318	—
Total revenues	1,043	1,104	41,213	2,855
Operating costs and expenses:				
Cost of product revenues ⁽¹⁾	5	139	3,609	400
Contract manufacturing costs	300	—	636	—
Research and development	7,387	7,290	23,652	21,176
Selling, general and administrative	4,698	9,382	18,676	28,348
Restructuring costs	282	—	4,246	—
Total operating costs and expenses	12,672	16,811	50,819	49,924
Loss from operations	(11,629)	(15,707)	(9,606)	(47,069)
Interest and other income (expense), net	(554)	414	(1,292)	1,414
Net loss	(12,183)	(15,293)	(10,898)	(45,655)
Change in unrealized gains or losses on available-for-sale securities	(20)	5	11	29
Comprehensive loss	\$ (12,203)	\$ (15,288)	\$ (10,887)	\$ (45,626)
Net loss per share, basic and diluted	\$ (0.31)	\$ (0.39)	\$ (0.28)	\$ (1.18)
Weighted-average number of common shares outstanding, basic and diluted	39,312	38,940	39,246	38,542

(1) Includes \$3,494,000 Finished Goods write-off in the first quarter of 2020 related to the Dechra Asset Purchase Agreement, consistent with the transition to proprietary Dechra branding and regulatory best practices related to label transitions on asset sale.

The accompanying notes are an integral part of these condensed consolidated financial statements.

Kindred Biosciences, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

	Nine months ended September 30,	
	2020	2019
Cash Flows from Operating Activities		
Net loss	\$ (10,898)	\$ (45,655)
Adjustments to reconcile net loss to net cash used in operating activities:		
Stock-based compensation expense	6,081	5,588
Shares issued for consulting services	—	61
Depreciation and amortization expense	3,473	1,761
Loss on disposal of property and equipment	54	134
Amortization of discount on marketable securities	(113)	(419)
Amortization of debt discount of long-term loan	259	—
Finished goods write off related to Dechra asset purchase ⁽¹⁾	3,494	—
Changes in operating assets and liabilities:		
Accounts receivable	184	102
Inventories	338	(653)
Prepaid expenses and other	(1,791)	141
Accounts payable	(955)	1,691
Accrued liabilities and accrued compensation	(3,423)	(5,398)
Net cash used in operating activities	(3,297)	(42,647)
Cash Flows from Investing Activities		
Purchases of investments	(70,059)	(89,079)
Sales of investments	—	2,999
Maturities of investments	77,520	55,678
Purchases of property and equipment	(3,040)	(7,281)
Proceeds from sale of property and equipment	82	3
Net cash provided by (used in) investing activities	4,503	(37,680)
Cash Flows from Financing Activities		
Exercises of stock options and purchase of ESPP shares	288	1,368
Payment of restricted stock tax liability on net settlement	(866)	(493)
Net proceeds from sale of common stock	—	43,125
Proceeds from loan payable, net of debt issuance costs	—	19,189
Net cash (used in) provided by financing activities	(578)	63,189
Net change in cash and cash equivalents	628	(17,138)
Cash and cash equivalents at beginning of period	15,986	56,302
Cash and cash equivalents at end of period	\$ 16,614	\$ 39,164

(1) Includes \$3,494,000 Finished Goods write-off in the first quarter of 2020 related to the Dechra Asset Purchase Agreement, due to the transition to proprietary Dechra brand labelling on asset sale.

Supplemental disclosure of non-cash investing and financing activities:

Purchases of property and equipment included in accounts payable and accrued liabilities	\$ 46	\$ 1,488
--	-------	----------

The accompanying notes are an integral part of these condensed consolidated financial statements.

Kindred Biosciences, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)

1. Description of Business, Basis of Presentation and Summary of Significant Accounting Policies

Kindred Biosciences, Inc. ("KindredBio", "we", "us" or "our") was incorporated on September 25, 2012 (inception) in the State of Delaware. On April 25, 2016, we filed a Certificate of Incorporation with the State of Delaware for a wholly owned subsidiary, KindredBio Equine, Inc. ("KindredBio Equine"). KindredBio Equine has one class of capital stock which is designated common stock, \$0.0001 par value per share. The authorized number of shares of common stock for KindredBio Equine is 1,000. On February 1, 2019, we filed a Certificate of Incorporation with the State of Delaware for a wholly owned subsidiary, Centaur Biopharmaceutical Services, Inc. ("Centaur Biopharmaceutical Services"). Centaur Biopharmaceutical Services has one class of capital stock which is designated common stock, \$0.0001 par value per share. The authorized number of shares of common stock for Centaur Biopharmaceutical Services is 1,000.

We are a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Our activities since inception have consisted principally of raising capital, establishing facilities, recruiting management and technical staff and performing research and development and advancing our product candidates seeking regulatory approval. Our headquarters are located in Burlingame, California.

Our first product, Mirataz® (mirtazapine transdermal ointment) was approved in May 2018 and became commercially available to veterinarians in the United States in July 2018. In November 2019, our second product, Zimeta™ (dipyron injection) for the control of fever in horses was approved by the FDA and became commercially available in December 2019. In addition, we have multiple other product candidates, including several biologics, in various stages of development.

On March 16, 2020, we entered into an Asset Purchase Agreement whereby we agreed to sell Mirataz, our transdermal drug for the management of weight loss in cats, to Dechra Pharmaceuticals PLC ("Dechra") for a cash purchase price of \$43 million, of which \$38.7 million will be paid on the closing date and \$4.3 million will be paid out of escrow beginning in 12 months assuming no escrow claims, alongside an ongoing royalty on global net sales. The acquisition comprises worldwide marketing rights, intellectual property rights, marketing authorizations and associated regulatory documentation, third party supply contracts related to raw material and manufacture of the finished product, and certain product inventory. On April 15, 2020, we completed the sale of Mirataz to Dechra.

Concurrent with the sale of Mirataz, we announced a strategic realignment of our business model whereby we plan to rely more on a partnership-based model for commercialization strategy similar to the traditional human biotech commercialization strategy whereby pipeline assets are partnered with larger commercial partners that can maximize product opportunity in return for upfront payments, contingent milestones, and royalties on future sales. Our focus will be on accelerating our deep pipeline of late-stage biologics candidates in canine and feline markets, while stopping small molecule development for these species. We believe monoclonal antibodies are the future of veterinary medicine, and represent the greatest opportunity for value creation, given large potential markets for our programs and our competitive advantage in biologics. Accordingly, the companion animal commercial infrastructure will be substantially reduced. In connection with this restructuring, we eliminated 53 positions and recorded a restructuring charge of approximately \$1.7 million related to severance payments and health care benefits, exclusive of stock compensation, representing about one-third of our workforce. The eliminated positions primarily relate to the companion animal sales force and research and development for small molecule programs.

On June 8, 2020, we announced a plan to strengthen our strategic position by, among other things, prioritizing our most attractive late stage programs and substantially reducing our expenses to best position the Company for success with the previously announced business model. This restructuring reduced our workforce by approximately 24 employees and resulted in a restructuring charge of approximately \$2.3 million related to severance payments and health care benefits, exclusive of stock compensation. We further eliminated another 5 positions and incurred a restructuring charge of approximately \$0.3 million related to severance payments and health care benefits in the third quarter of 2020. We have completed our restructuring and do not anticipate any significant further reductions in our workforce for the foreseeable future.

We are subject to risks common to companies in the biotechnology and pharmaceutical industries. There can be no assurance that our research and development will be successfully completed, that adequate patent or other intellectual property protection for our technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. We operate in an environment of substantial competition

from other animal health companies. In addition, we are dependent upon the services of our employees and consultants, as well as third-party contract research organizations and manufacturers.

Our contract manufacturers purchase raw materials from suppliers located in China and India in order to manufacture our products and product candidates. The December 2019 outbreak of the novel strain of coronavirus (COVID-19) in China and India and other countries with which we do business may result in the full or partial shutdown of manufacturers or other businesses that are affected by the coronavirus, which may adversely impact both our ability to obtain sufficient and timely supplies of our products and other product candidates and our revenue from those products. In addition to adversely affecting our ability to obtain sufficient and timely supplies of products and product candidates from suppliers, any outbreak of contagious diseases, such as the recent novel strain of coronavirus (COVID-19) that is affecting the global community, could adversely affect our business and operations in other ways, many of which cannot currently be determined or quantified. These uncertain factors, including the duration of the outbreak, the severity of the disease and the actions to contain or treat its impact, could impair our operations including, among others, employee mobility and productivity, availability of facilities, conduct of our clinical trials, manufacturing and supply capacity, and availability and productivity of third party service suppliers.

The accompanying unaudited interim condensed consolidated financial statements ("financial statements") have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("U.S. GAAP") for complete financial statements. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2019 included in our annual report on Form 10-K as filed with the SEC on March 16, 2020. In the opinion of management, all adjustments, consisting of a normal and recurring nature, considered necessary for a fair presentation, have been included in these financial statements.

The accompanying financial statements include the accounts of Kindred Biosciences and its wholly owned subsidiaries (the "Company"). All inter-company accounts and transactions have been eliminated in consolidation.

Stock Offerings

In January 2019, we completed a public offering of 4,847,250 shares of common stock, which includes the exercise in full of the underwriters' option to purchase 632,250 additional shares of our common stock, at a public offering price of \$9.50 per share for total gross proceeds of approximately \$46,049,000. Net proceeds, after deducting underwriting discounts and commissions and offering expense, were approximately \$43,125,000. On April 8, 2020, we entered into an At Market Offering ("ATM") whereby we may offer and sell shares of our common stock from time to time up to \$25 million. As of September 30, 2020, no shares were sold through the ATM.

Borrowings

On September 30, 2019, we entered into a Loan and Security Agreement (the "Loan Agreement") with Solar Capital Ltd., as collateral agent and lender, and the other lenders named in the Loan Agreement (Solar Capital Ltd. and the other lenders collectively, the "Lenders"). The Lenders have agreed to make available to KindredBio an aggregate principal amount of up to \$50.0 million under the Loan Agreement. We plan to use the loan proceeds to support the development and commercialization of our products and product candidates as well as for working capital and general corporate purposes. The Loan Agreement provides for a term loan commitment of \$50.0 million in three tranches: (1) a \$20.0 million term A loan that was funded on September 30, 2019; (2) a \$15.0 million term B loan that is to be funded at our request, subject to certain conditions described in the Loan Agreement being satisfied, no later than December 31, 2020; and (3) a \$15.0 million term C loan that is to be funded at our request, subject to certain conditions described in the Loan Agreement being satisfied, on or before June 30, 2021. Each term loan has a maturity date of September 30, 2024. Each term loan bears interest at a floating per annum rate equal to the one-month LIBOR rate (with a floor of 2.17%) plus 6.75%. We are permitted to make interest-only payments on each term loan through October 31, 2021. The interest-only period can be extended by six months upon our satisfaction of the minimum liquidity requirements described in the Loan Agreement. See Note 6.

On March 16, 2020, we entered into a First Amendment to Loan and Security Agreement (the "First Amendment") with the Lenders in connection with the sale of our Mirataz asset. Among other things, the First Amendment increases the minimum cash amount, as defined in the Loan Agreement, required to be maintained by KindredBio to \$10,000,000 at any time prior to the initial funding date of any term B loan, to \$15,000,000 at all times on and after the initial funding date of any term B loan, and to \$20,000,000 at all times on and after the initial funding date of any term C loan, and releases Solar Capital's lien in and to

the assets that are being sold by KindredBio. We agreed to pay an amendment fee of One Hundred Thousand Dollars (\$100,000), which was deemed fully earned and non-refundable on the First Amendment's effective date. The First Amendment also requires KindredBio to receive unrestricted net proceeds of at least \$10,000,000 prior to December 31, 2021 pursuant to a specified sale of preferred or common stock or convertible subordinated debt financing.

Liquidity

We have incurred losses and negative cash flows from operations and had an accumulated deficit of \$233,957,000 as of September 30, 2020. We expect to continue to incur losses and negative cash flows as we continue our product development activities, seek regulatory approvals for our product candidates, establish a biologics manufacturing capability, and commercialize any approved products. To date, we have been funded primarily through sales of our equity and recently through an asset sale. We might require additional capital until such time as we can generate operating revenues in excess of operating expenses. We believe that our cash, cash equivalents and investments totaling \$66,837,000 as of September 30, 2020, the net reduction in our workforce, remaining proceeds from the Mirataz sale, and revenues from royalties and contract manufacturing will be sufficient to fund our planned operations through mid-2022. In addition, the potential additional draw down of \$30 million from our Loan Agreement, which is contingent on the achievement of certain milestones, and our April 8, 2020 ATM facility will provide us with access to additional cash and extend our runway, if required.

If we require additional funding for operations, we may seek such funding through public or private equity or debt financings or other sources, such as corporate collaborations and licensing arrangements. We may not be able to obtain financing on acceptable terms, or at all, and we may not be able to enter into corporate collaborations or licensing arrangements. The terms of any financing may result in dilution or otherwise adversely affect the holdings or the rights of our stockholders.

Revenue Streams

Except for the normal product sales, our revenue includes revenue from the sale of our Mirataz asset, the associated partner royalties and revenue from our contract manufacturing service.

Product revenue

Our product revenues consist of product revenues resulting from the sales of Mirataz through April, 2020 and Zimeta. We account for a contract with a customer when there is a legally enforceable contract between us and our customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Our customers could either be distributors who subsequently resell our products to third parties such as veterinarians, clinics or animals hospitals or the third parties themselves. Included in product sale is revenue derived from co-marketing products for our partners in conjunction with sales of Mirataz and Zimeta.

Revenue from asset sale

On March 16, 2020, we entered into an Asset Purchase Agreement to sell Mirataz to Dechra for a cash purchase price of \$43 million. On April 15, 2020, we completed the sale of Mirataz to Dechra and received payment of \$38.7 million on the closing date. The remaining \$4.3 million will be paid out of escrow beginning in 12 months assuming no escrow claims. We concluded our accounting treatment of the asset sale to Dechra meets the scope of Accounting Standards Codification, Topic "ASC 610-20-15-2", *Gains and Losses from the Derecognition of Nonfinancial Assets*. We considered our strategic realignment of our business model whereby we become a biologics-only company focused on accelerating our deep pipeline of late-stage biologics candidates in canine and feline markets. Accordingly, we plan to rely more on a partnership-based model for commercialization strategy whereby pipeline assets are partnered with larger commercial partners that can maximize product opportunity in return for upfront payment, contingent milestones, and royalties on future sales. Based on the above evaluation in the aggregate, we concluded the proper presentation of the sale of Mirataz within operating income as part of revenue. This is presented as a separate line item and described as revenue from asset sale.

Partner royalties

Related to the Dechra Asset Purchase Agreement, Dechra will pay us a royalty based on a percentage of worldwide Net Sales, on a country-by-country basis. Net sales is defined as gross invoiced sales amount less discounts and allowances, taxes on sales, shipping charges if included in invoice price, qualified returns and chargebacks. Revenue for each quarter is accrued

based on a statement furnished by Dechra and adjustments made, if any, to be in line with payment received within forty-five days of the end of the applicable calendar quarter.

Contract manufacturing revenue

The manufacturing revenue stream generally represents revenue from the manufacturing of customer product(s) recognized over time, utilizing an input method that compares the cost of cumulative work-in-process to date to the most current estimate for the entire cost of the performance obligation through manufacturing runs. Under a manufacturing contract, a quantity of manufacturing runs is ordered and the product is manufactured according to the customer's specifications and typically only one performance obligation is included. Each manufacturing run represents a distinct service that is sold separately and has stand-alone value to the customer. The product(s) are manufactured exclusively for a specific customer and have no alternative use. The customer retains control of their product during the entire manufacturing process and can make changes to the process or specifications at their request.

The customer and our project team typically have a timeline on each milestone and duration time. They also have an estimated start and finish date. When the project is moving forward, they constantly change to the actual date to track the project progress. The timing has been shared by both parties. This becomes the most important basis for our revenue recognition.

Because of the timing effect of revenue recognition, billings and cash collections can be recorded into three different ways: billed trade receivables, contract assets (unbilled receivables), and contract liabilities (customer deposits and deferred revenue). Contract assets are recorded when our right to consideration is conditioned on something other than the passage of time. Contract assets are reclassified to trade receivables on the balance sheet when our rights become unconditional. Contract liabilities represent customer deposits and deferred revenue billed and/or received in advance of our fulfillment of performance obligations. Contract liabilities convert to revenue as we perform our obligations under the contract.

Revenue Recognition

We account for a contract with a customer when there is a legally enforceable contract between us and our customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Our customers could either be distributors who subsequently resell our products to veterinarians, clinics or animals hospitals, licensing partners or third parties.

In accordance with FASB Accounting Standards ASC 606, Revenue from Contracts with Customers, which we adopted on January 1, 2018, we applied the following steps to recognize revenue that reflects the consideration to which we expect to be entitled to receive in exchange for the promised goods or services:

1. Identify the contract with a customer

A contract with a customer exists when we enter into an enforceable contract with a customer. These contracts define each party's rights, payment terms and other contractual terms and conditions of the sale. We apply judgment in determining the customer's ability and intention to pay, which is based on published credit and financial information pertaining to the customer.

2. Identify the performance obligations in the contract

Our product in a given purchase order is delivered at the same time and we do not separate an individual order into separate performance obligations. We have concluded the sale of finished goods and related shipping and handling are accounted for as a single performance obligation as there are no other promises to deliver goods beyond what is specified in each accepted customer order. For contract manufacturing, we have concluded the milestone of each manufacturing service are accounted for as a single performance obligation as there are no other promises beyond what is specified in each accepted customer order.

3. Determine the transaction price

The transaction price is determined based on the consideration which we will be entitled to receive in exchange for transferring goods or service to the customer, typically a fixed consideration in our contractual agreements.

4. Allocate the transaction price to the performance obligations

The transaction price is allocated entirely to the performance obligation to provide pharmaceutical products or contract manufacturing service with each milestone its own price. The nature of the promises/obligations under our contracts is to transfer a distinct good or service. Accordingly, because a single performance obligation exists, including in each milestone pertaining to contract manufacturing, no allocation of the transaction price is necessary.

5. Determine the satisfaction of performance obligation

Revenue is recognized when control of the finished goods is transferred to the customer, net of applicable reserves for variable consideration. Control of the finished goods is transferred at a point in time, upon delivery to the customer.

For contract manufacturing service, revenue is recognized over time. Control of the finished manufactured products is transferred at a point in time, upon delivery to the customer.

Reserves for Variable Consideration

Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. Components of variable consideration include product returns, allowances and discounts. These estimates take into consideration a range of possible outcomes for the expected value (probability-weighted estimate) or relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized where the contract will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.

No reserves for contract manufacturing service are recorded as each manufacturing run represents a distinct service that is sold separately and has stand-alone value to the customer. The product(s) are manufactured exclusively for a specific customer and have no alternative use.

Product Returns

Consistent with the industry practice, we generally offer customers a limited right of return of damaged or expired product that has been purchased directly from us. Our return policy generally allows customers to receive credit for expired products within 90 days after the product's expiration date. We estimate the amount of our product revenues that may be returned by our customers and record these estimates as a reduction of product revenues in the period the related product revenues are recognized, as well as within accrued liabilities, in the consolidated balance sheets. We currently estimate product return liabilities using probability-weighted available industry data and data provided by the our distributors such as the inventories remaining in the distribution channel. To-date, we have no returns and believe that returns of our product in future periods will be minimal. We do not record a return asset associated with the returned damaged or expired goods due to such asset is deemed to be fully impaired at the time of product return.

Our contract manufacturing customer retains control of their product during the entire manufacturing process and can make changes to the process or specifications at their request. There are no product returns.

Sales Discounts and Allowances

We compensate our distributors for sales order management, data and distribution and other services through sales discounts and allowances. However, such services are not distinct from our sale of products to distributors and, therefore, these discounts and allowances are recorded as a reduction of product revenues in the consolidated statements of operations and comprehensive loss, as well as a reduction to accounts receivable in the consolidated balance sheets.

No discounts and allowances are recorded for contract manufacturing service as the price of each milestone is agreed upon when the contract is signed.

Sales Commissions

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses.

Cost of Revenues

Cost of product revenues consists primarily of the cost of direct materials, direct labor and overhead costs associated with manufacturing, inbound shipping and other third-party logistics costs.

Contract manufacturing costs consist primarily of the cost of direct materials, direct labor and overhead costs associated with manufacturing, rent, facility costs and related machinery depreciation.

Inventories

We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expire in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. In the quarter ended March 31, 2020, we wrote off \$3,494,000 Mirataz inventory related to the Dechra Asset Purchase Agreement, due to the transition to Dechra brand labelling. Currently our inventory consists of Zimeta finished goods only.

Property, Plant and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. We calculate depreciation using the straight-line method over the estimated useful lives of the assets, which range from two to five years for furniture, fixtures, lab and computer equipment and software, and fifteen to thirty-nine years for land improvements and real property. Land and assets held within construction in progress are not depreciated. Construction in progress is related to the construction or development of property and equipment that have not yet been placed in service for their intended use. Expenditures for repairs and maintenance of assets are charged to expense as incurred. We amortize leasehold improvements using the straight-line method over the estimated useful lives of the respective assets or the lease term, whichever is shorter. Upon retirement or sale, the cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts and any resulting gain or loss is included in other income/expense.

Use of Estimates

The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Estimates are based on historical experiences or on forecasts, including information received from third parties and other assumptions that the Company believes are reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.

Comprehensive Loss

Our comprehensive loss includes the change in unrealized gains or losses on available-for-sale debt securities. The cumulative amount of gains or losses are reflected as a separate component of stockholders' equity in the condensed consolidated balance sheets as accumulated other comprehensive loss.

Recently Issued Accounting Pronouncements

In March 2020, the FASB issued ASU No. 2020-04, "Reference Rate Reform (Topic 848)", changes to the interbank offered rates (IBORs), and, particularly, the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The

amendments provide optional expedients and exceptions for applying U.S. GAAP to contracts that reference LIBOR expected to be discontinued because of reference rate reform. The expedients and exceptions do not apply to contract modifications made after December 31, 2022. The following optional expedients are permitted for contracts that are modified because of reference rate reform and that meet certain scope guidance: Modifications of contracts within the scope of Topics 470, Debt, should be accounted for by prospectively adjusting the effective interest rate. The amendments also permit an entity to consider contract modifications due to reference rate reform to be an event that does not require contract remeasurement at the modification date or reassessment of a previous accounting determination. When elected, the optional expedients for contract modifications must be applied consistently for all contracts. It applies to all entities within the scope of the affected accounting guidance and will take effect as of March 12, 2020 through December 31, 2022. We have one loan contract which references LIBOR rate. We have not modified the contract with our lenders yet. We are currently evaluating the new guidance and have not determined the impact this standard may have on our financial statements.

We do not believe there are any other recently issued standards not yet effective that will have a material impact on our financial statements when the standards become effective.

2. Revenues and Cost of Revenues

Beginning with the second quarter of 2020, our revenues consist of product revenues from Mirataz and Zimeta, Mirataz asset sale, partner royalties and contract manufacturing. We account for a contract with a customer when there is a legally enforceable contract between us and our customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Our revenues are measured based on the consideration specified in the contract with each customer, net of product returns, discounts and allowances if applicable.

The following table summarizes revenues and costs for the three and nine months ended September 30, 2020 and 2019 (in thousands).

	Three months ended September 30,		Nine months ended September 30,	
	2020	2019	2020	2019
Revenues				
Net product sale revenues	\$ 16	\$ 1,104	\$ 782	\$ 2,855
Revenue from asset sale	—	—	38,700	—
Partner royalty revenue	255	—	413	—
Contract manufacturing revenue	772	—	1,318	—
Total revenues	1,043	1,104	41,213	2,855
Costs of revenues				
Cost of product sales ⁽¹⁾	5	139	3,609	400
Contract manufacturing costs	300	—	636	—
Total costs of revenues	305	139	4,245	400
Gross margin	\$ 738	\$ 965	\$ 36,968	\$ 2,455

(1) Includes \$3,494,000 Finished Goods write-off in the first quarter of 2020 related to the Dechra Asset Purchase Agreement, consistent with the transition to proprietary Dechra branding and regulatory best practices related to label transitions on asset sale.

Concentrations of credit risk

Our net product revenue was generated entirely from sales within the United States. Our product sales to two large distributors, namely Covetrus and Midwest Veterinary Supply, and three large distributors, namely MWI Animal Health, Covetrus and Midwest Veterinary Supply, each accounted for more than 10% of gross product revenues for the three and nine months ended September 30, 2020. Approximately 100% and 75% of our gross product revenues were to two and three distributors for the three and nine months ended September 30, 2020, respectively. Three distributors attributed to

approximately 84% and 85% of our gross product revenues for the three and nine months ended September 30, 2019, respectively.

Our accounts receivable from amounts billed for contract manufacturing services for the year to date of 2020 is derived from one customer. The contract requires up-front payment and installment payments during the service period. We perform periodic evaluations of the financial condition of our customers and generally do not require collateral, but we can terminate any contract if a material default occurs.

Product returns

Our return policy generally allows customers to receive credit for expired products within 90 days after the product's expiration date. We currently estimate product return liabilities of 3% for Zimeta of gross product revenue using probability-weighted available industry data and data provided by our distributors such as the inventories remaining in the distribution channel. Adjustments will be made in the future if actual results vary from our estimates.

Accounts receivable and allowance for doubtful accounts

Accounts receivable are stated at their carrying values, net of any allowances for doubtful accounts. Accounts receivable consist primarily of amounts due from distributors, for which collection is probable based on the customer's intent and ability to pay. Receivables are evaluated for collection probability on a regular basis and an allowance for doubtful accounts is recorded, if necessary. We have no allowance for doubtful accounts as of September 30, 2020 and December 31, 2019 as our analysis did not uncover any collection risks.

Contract assets

Because of the timing effect of revenue recognition, billings and cash collections can be recorded into three different ways: billed trade receivables, contract assets (unbilled receivables), and contract liabilities (customer deposits and deferred revenue). Contract assets are recorded when our right to consideration is conditioned on something other than the passage of time. Contract assets are reclassified to trade receivables on the balance sheet when our rights become unconditional. Contract liabilities represent customer deposits and deferred revenue billed and/or received in advance of our fulfillment of performance obligations. Contract liabilities convert to revenue as we perform our obligations under the contract. Contract assets as of September 30, 2020 were \$695,000, which was recorded under other current assets. There were no contract assets in 2019.

3. Fair Value Measurements

Certain assets and liabilities are carried at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The carrying amount of financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to the short maturities of these financial instruments. Financial assets, which consist of money market funds and available-for-sale securities, are measured at fair value on a recurring basis.

Financial assets, which consist of money market funds and available-for-sale securities, are measured at fair value on a recurring basis and are summarized as follows (in thousands):

Fair Value Measurements as of September 30, 2020				
Description	Total	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)
Cash equivalents:				
Money market funds	\$ 4,050	\$ 4,050	\$ —	\$ —
U.S. treasury bills	8,002	8,002	—	—
Commercial paper	2,900	—	2,900	—
Corporate notes	160	—	160	—
Short-term investments:				
U.S. treasury bills	3,544	3,544	—	—
U.S. government agency notes	33,509	—	33,509	—
Commercial paper	4,699	—	4,699	—
Corporate notes	3,971	—	3,971	—
Long-term investments:				
U.S. government agency notes	4,500	—	4,500	—
	<u>\$ 65,335</u>	<u>\$ 15,596</u>	<u>\$ 49,739</u>	<u>\$ —</u>

Fair Value Measurements as of December 31, 2019				
Description	Total	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)
Cash equivalents:				
Money market funds	\$ 1,592	\$ 1,592	\$ —	\$ —
Commercial paper	13,580	—	13,580	—
Short-term investments:				
U.S. treasury bills	8,524	8,524	—	—
Commercial paper	25,573	—	25,573	—
U.S. government agency notes	11,461	—	11,461	—
Corporate notes	10,165	—	10,165	—
Long-term investments:				
U.S. government agency notes	801	—	801	—
Corporate notes	1,036	—	1,036	—
	<u>\$ 72,732</u>	<u>\$ 10,116</u>	<u>\$ 62,616</u>	<u>\$ —</u>

During the nine months ended September 30, 2020, there were no transfers of assets between Level 1, Level 2 or Level 3 of the fair value hierarchy.

At September 30, 2020 and December 31, 2019, we did not have any financial liabilities which were measured at fair value on a recurring basis.

4. Investments

We classify all highly-liquid investments with stated maturities of greater than three months from the date of purchase and remaining maturities of less than one year as short-term investments. Investments with maturities beyond one year may be classified as short-term based on their highly liquid nature and because such investments are viewed as being available to support current operations. We classify and account for investments as available-for-sale and reflect realized gains and losses using the specific identification method. Changes in market value, if any, excluding other-than-temporary impairments, are reflected in other comprehensive income (loss).

The fair value of available-for-sale investments by type of security at September 30, 2020 was as follows (in thousands):

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Short-term investments:				
Commercial paper	\$ 4,696	\$ 3	\$ —	\$ 4,699
U.S. treasury bills	3,544	—	—	3,544
U.S. government agency notes	33,500	11	(2)	33,509
Corporate notes	3,960	11	—	3,971
	<u>45,700</u>	<u>25</u>	<u>(2)</u>	<u>45,723</u>
Long-term investments:				
U.S. government agency notes	4,498	2	—	4,500
	<u>4,498</u>	<u>2</u>	<u>—</u>	<u>4,500</u>
Total available-for-sale investments	\$ 50,198	\$ 27	\$ (2)	\$ 50,223

The fair value of available-for-sale investments by type of security at December 31, 2019 was as follows (in thousands):

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Short-term investments:				
U.S. treasury bills	\$ 8,517	\$ 7	\$ —	\$ 8,524
Commercial paper	25,576	3	(6)	25,573
U.S. government agency notes	11,460	2	(1)	11,461
Corporate notes	10,157	8	—	10,165
	<u>55,710</u>	<u>20</u>	<u>(7)</u>	<u>55,723</u>
Long-term investments:				
U.S. government agency notes	801	—	—	801
Corporate notes	1,036	—	—	1,036
	<u>1,837</u>	<u>—</u>	<u>—</u>	<u>1,837</u>
Total available-for-sale investments	\$ 57,547	\$ 20	\$ (7)	\$ 57,560

5. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30, 2020	December 31, 2019
Accrued consulting	\$ 374	\$ 589
Accrued research and development costs	940	1,336
Other expenses	697	2,206
	<u>\$ 2,011</u>	<u>\$ 4,131</u>

6. Borrowings

On September 30, 2019, we entered into the Loan and Security Agreement with Solar Capital Ltd. The Lenders have agreed to make available to KindredBio an aggregate principal amount of up to \$50.0 million under the Loan Agreement. We plan to use the loan proceeds to support the development and commercialization of our products and product candidates as well as for working capital and general corporate purposes. The Loan Agreement provides for a term loan commitment of \$50.0 million in three tranches: (1) a \$20.0 million term A loan that was funded on September 30, 2019; (2) a \$15.0 million term B loan that is to be funded at our request, subject to certain conditions described in the Loan Agreement being satisfied, no later than December 31, 2020; and (3) a \$15.0 million term C loan that is to be funded at our request, subject to certain conditions described in the Loan Agreement being satisfied, on or before June 30, 2021. Each term loan has a maturity date of September 30, 2024. Each term loan bears interest at a floating per annum rate equal to the one-month LIBOR rate (with a floor of 2.17%) plus 6.75%. We are permitted to make interest-only payments on each term loan through October 31, 2021. The interest-only period can be extended by six months upon our satisfaction of the minimum liquidity requirements described in the Loan Agreement. We have agreed to maintain cash at all times equal to at least \$5.0 million prior to the funding of the term B loan, at least \$10.0 million after the funding of the term B loan and at least \$15.0 million after the funding of the term C loan, plus in each case the amount of our accounts payable that have not been paid within 90 days from the invoice date subject to certain exceptions. Equal monthly payments of principal will be due and payable commencing at the end of the interest-only period of the term loans. In connection with the term loan, we incurred closing costs of \$819,000, which are shown net of the proceeds and will be amortized over the term of the loan using the effective interest method. We are obligated to pay a facility fee in the amount of 0.50% of each term loan that is funded and a non-utilization fee in the amount of 0.25% of each term B loan and term C loan to the extent that such loans are not funded. We are obligated to pay a final fee equal to 3.60% of the aggregate amount of the term loans funded (or 4.35% of such funded loans if the interest-only period is extended as described above), such final fee to be due and payable upon the earliest to occur of (1) the maturity date, (2) the acceleration of the term loans, and (3) the prepayment of the term loans. We have the option to prepay all, but not less than all, of the outstanding principal balance of the term loans under the Loan Agreement. If we prepay the term loans prior to the maturity date, we must pay the Lenders a prepayment premium fee based on a percentage of the outstanding principal balance, equal to 3.0% if the payment occurs on or before September 30, 2020, 2.0% if the prepayment occurs after September 30, 2020 but on or before September 30, 2021, or 1.0% if the prepayment occurs after September 30, 2021. Our obligations under the Loan Agreement are secured by a first-priority security interest in substantially all of KindredBio's assets, including our intellectual property, and a lien on our real property. The Loan Agreement contains customary representations, warranties and covenants and also includes customary events of default, including payment defaults, breaches of covenants, and a default upon the occurrence of a material adverse change affecting us. Upon the occurrence of an event of default, a default interest rate of an additional 5.00% per annum may be applied to the outstanding loan balance, and the Lenders may declare all outstanding obligations immediately due and payable and exercise all their rights and remedies as set forth in the Loan Agreement and under applicable law. We were in compliance with all covenants as of September 30, 2020.

In conjunction with the Dechra Asset Purchase Agreement, on March 16, 2020, we entered into a First Amendment to Loan and Security Agreement (the "First Amendment") with the Lenders in connection with the sale of our Mirataz asset. Among other things, the First Amendment increases the minimum cash amount, as defined in the Loan Agreement, required to be maintained by KindredBio to \$10,000,000 at any time prior to the initial funding date of any term B loan, to \$15,000,000 at all times on and after the initial funding date of any term B loan, and to \$20,000,000 at all times on and after the initial funding date of any term C loan, and releases Solar Capital's lien in and to the assets that are being sold by KindredBio. We agreed to pay an amendment fee of One Hundred Thousand Dollars (\$100,000), which shall be deemed fully earned and non-refundable.

on the First Amendment's effective date. The First Amendment also requires KindredBio to receive unrestricted net proceeds of at least \$10,000,000 prior to December 31, 2021 pursuant to a specified sale of preferred or common stock or convertible subordinated debt financing.

As of September 30, 2020, assuming the principal payments start on November 1, 2021, our future debt payment obligations towards the principal and final fee, excluding interest payments and exit fee, for the respective fiscal years are as follows (in thousands):

2020	\$	—
2021		1,111
2022		6,667
2023		6,667
2024		6,275
Total principal and final fee payments		20,720
Less: Unamortized debt issuance costs		(620)
Less: Unaccreted value of final fee		(576)
Loan payable, long term	\$	19,524

7. Common Stock and Stock-Based Awards

Common Stock

During the nine months ended September 30, 2020, we issued 29,775 shares of common stock in connection with the exercise of stock options for gross proceeds of \$179,000, vested 326,196 restricted stock awards and restricted stock units and withheld 33,959 shares of restricted stock awards and 95,748 shares related to restricted stock units to satisfy employee tax withholding obligations arising in conjunction with the vesting of restricted stock and restricted stock units (see below).

Stock-Based Awards

The table below shows the number of shares of common stock underlying options granted to employees, directors and consultants, the assumptions used in the Black-Scholes option pricing model used to value those options and the resulting weighted-average grant date fair value per share:

Stock Option Plan	Three months ended September 30,		Nine months ended September 30,	
	2020	2019	2020	2019
Shares underlying options granted	24,000	22,000	774,000	1,071,500
Weighted-average exercise price	\$4.11	\$7.46	\$9.62	\$9.85
Weighted average risk-free interest rate	0.34 %	1.69 %	1.49 %	2.52 %
Weighted average expected term (years)	6.1	6.1	6.2	5.9
Weighted average expected volatility	63%	56%	55%	57%
Expected dividend yield	—	—	—	—
Weighted-average grant date fair value per share	\$2.33	\$3.99	\$4.92	\$5.39

In June 2018, we adopted the 2018 Equity Incentive Plan (the "2018 Plan"), and reserved 3,000,000 shares of our common stock for issuance under the 2018 Plan. At the Annual Meeting of Stockholders of the Company held on June 15, 2020 (the "2020 Annual Meeting"), our stockholders approved an amendment to the 2018 Equity Incentive Plan (as amended, the "2018 Plan") to increase the number of shares of common stock authorized for issuance by 1,600,000 shares. The 2018 Plan is the successor to our 2016 Equity Incentive Plan (the "2016 Plan"), which was retired on June 21, 2018 upon stockholders' approval of our 2018 Plan. The 2016 Plan was the successor to our 2012 Equity Incentive Plan (the "2012 Plan"), which was retired on May 23, 2016 upon stockholders' approval of our 2016 Plan. All awards made under the 2016 and 2012 Plans shall

remain subject to the terms of these plans. Options granted under the 2018 Plan may be either incentive stock options or nonstatutory stock options. The 2018 Plan also provides for the grant of stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards. The exercise price of a stock option may not be less than 100% of the closing price of our common stock on the date of the grant. If, at any time we grant an incentive stock option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of KindredBio stock, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant. Options generally vest over a period of one or four years from the date of grant. Options granted under the 2018 Plan expire no later than 10 years from the date of grant. As of September 30, 2020, there were 2,079,932 option shares outstanding, and 1,901,576 shares available for future grants under the 2018 Plan.

Our Employee Stock Purchase Plan (the "Stock Purchase Plan" or "ESPP"), adopted in December 2014, permits eligible employees to purchase common stock at a discount through payroll deductions during defined six-month consecutive offering periods beginning December 1 with the exception of our first offering period which commenced on January 1, 2015 for a five month duration. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock on the first day of the offering or 85% of the fair market value of our common stock on the purchase date. A total of 200,000 shares of common stock are authorized for issuance under the Stock Purchase Plan. At the Annual Meeting of Stockholders of Kindred Biosciences, Inc. held on June 22, 2018, our stockholders approved an amendment to increase the number of shares that may be issued under the ESPP from 200,000 shares to 500,000 shares. A participant may purchase a maximum of 2,000 shares of common stock during each offering period, not to exceed \$25,000 worth of common stock on the offering date during each calendar year.

We use the Black-Scholes option pricing model, in combination with the discounted employee price, in determining the value of the Stock Purchase Plan expense to be recognized during each offering period. The following assumptions were used in the Black-Scholes option pricing model to calculate employee stock-based compensation:

Stock Purchase Plan	Three months ended September 30,		Nine months ended September 30,	
	2020	2019	2020	2019
Weighted average risk-free interest rate	0.18%	2.35%	0.91%	2.44%
Weighted average expected term (years)	0.5	0.5	0.5	0.5
Weighted average expected volatility	124.5%	41.6%	88.5%	44.9%
Expected dividend yield	—	—	—	—
Weighted-average grant date fair value per share	\$2.08	\$2.02	\$2.14	\$2.84

Under the Stock Purchase Plan, employees purchased 29,797 shares of common stock for \$109,000 during the nine months ended September 30, 2020. At September 30, 2020 and December 31, 2019, we had an outstanding liability of \$68,000 and \$40,000, respectively, which is included in accrued compensation on the condensed consolidated balance sheets, for employee contributions to the Stock Purchase Plan for shares pending issuance at the end of the next offering period.

We recorded stock-based compensation expense as follows (in thousands):

	Three months ended September 30,		Nine months ended September 30,	
	2020	2019	2020	2019
Research and development	\$ 434	\$ 475	\$ 1,496	\$ 1,408
General and administrative	1,660	1,351	4,585	4,180
	<u>\$ 2,094</u>	<u>\$ 1,826</u>	<u>\$ 6,081</u>	<u>\$ 5,588</u>

We had an aggregate of approximately \$5,602,000 of unrecognized stock-based compensation expense for options outstanding and the Stock Purchase Plan as of September 30, 2020 which is expected to be recognized over a weighted-average period of 2.3 years.

Restricted Stock Award and Restricted Stock Units

On January 23, 2017, we granted 250,000 shares of restricted stock awards to four employees. Shares will vest 25% on each one year anniversary of the grant date provided that the employee is in the employment of the Company on such vesting date. On January 22, 2018, we granted 315,000 shares of restricted stock units to four employees. Shares will vest 25% on each one year anniversary of the grant date provided that the employee is in the employment of the Company on such vesting date. In Q1 2019, we granted 300,775 shares of restricted stock units to most of our employees. Shares will vest 25% on each one year anniversary of the grant date provided that the employee is in the employment of the Company on such vesting date. In Q1 2020, we granted 586,915 shares of restricted stock units to most of our employees. Shares will vest 25% on each one year anniversary of the grant date provided that the employee is in the employment of the Company on such vesting date. In July 2020, we granted 51,750 shares of restricted stock units to most of our employees except officers. Shares will vest 100% on the one year anniversary of the grant date provided that the employee is in the employment of the Company on such vesting date. The total stock-based compensation expense related to all awards and units is \$12,864,000. As of September 30, 2020, we have an aggregate of approximately \$4,578,000 unrecognized stock-based compensation expense for restricted stock awards and units outstanding which is expected to be recognized over a weighted-average period of 2.7 years.

Restricted stock award and restricted stock units activity for nine months ended September 30, 2020 was as follows:

Restricted Stock Award / Restricted Stock Units	Shares	Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2019	625,325	\$9.01
Granted	638,665	9.38
Vested	(326,196)	8.60
Forfeited	(287,467)	9.97
Unvested balance at September 30, 2020	650,327	\$9.16

Stock Option Information

A summary of stock option activity under all stock plans for the nine months ended September 30, 2020, is presented as follows:

Stock Options	Number of Outstanding	Weighted Average Exercise Price Per Share
Balance at December 31, 2019	6,353,370	\$7.94
Granted	774,000	9.62
Exercised	(29,775)	5.51
Forfeited	(293,679)	10.07
Expired	(209,181)	9.43
Balance at September 30, 2020	6,594,735	\$8.00

As of September 30, 2020, options to purchase 5,363,225 shares of common stock were exercisable at a weighted average price of \$7.67 per share.

Equity Award Modifications**Stock Option Modifications**

In connection with our restructuring, we eliminated 82 positions year-to-date as of September 30, 2020. We extended the post-employment exercise periods of vested stock options for 78 employees in connection with their separation from the Company. We accounted for the extension as a modification of an equity award under ASC 718. Accordingly, we recognized incremental stock compensation expense of approximately \$120,000 through September 30, 2020.

Accelerating vesting of stock grants

On July 31, 2020, Ms. Bevers, our previous President and Chief Operating Officer, and KindredBio entered into a Severance and Release Agreement (the "Severance Agreement") which provides, among other things, that Ms. Bevers is entitled to receive the severance compensation and benefits that are described in Section 4(c) of her Amended and Restated Executive Employment Agreement dated May 22, 2018, as amended by Amendment No. 1 dated October 19, 2018, that KindredBio previously filed with the Securities and Exchange Commission. Ms. Bevers is entitled to accelerated vesting in full of all of her outstanding stock options and other equity awards granted by KindredBio. On July 31, 2020, we accelerated the vesting all Ms. Bevers' stock options and other equity awards granted and accounted it as a modification of an equity award under ASC 718. Accordingly, we recognized stock compensation expense of approximately \$547,000 for this transaction through September 30, 2020.

8. Stockholders' Equity

Stockholders' Equity

The following tables present the changes in stockholders' equity (in thousands):

	Three months ended September 30, 2020							
	Common stock		Additional Paid in Capital	Accumulated Comprehensive Income	Accumulated Other Comprehensive Income	Accumulated Deficit	Stockholders' Equity	
Shares	Amount							
Balance at June 30, 2020	39,333	\$ 4	\$ 308,542	\$ 44	\$ (221,774)	\$ 86,816		
Comprehensive income								
Net loss	—	—	—	—	(12,183)	(12,183)		
Change in unrealized gains on available for sale securities	—	—	—	(20)	—	(20)		
Total comprehensive loss						(12,203)		
Stock-based compensation expenses	—	—	2,094	—	—	2,094		
RSU issuance of shares when vested ⁽¹⁾	48	—	(156)	—	—	(156)		
Shares withheld related to net share settlement of equity awards ⁽²⁾	(12)	—	(41)	—	—	(41)		
Exercise of common stock options	3	—	27	—	—	27		
Balance at September 30, 2020	39,372	\$ 4	\$ 310,466	\$ 24	\$ (233,957)	\$ 76,537		

(1) In Q3 2020, 95,000 RSU shares were vested, 47,898 shares were released, 47,102 shares were forfeited to cover tax liability.

(2) In Q3 2020, 25,000 RSA shares were vested, 12,604 shares were released, 12,396 shares were forfeited to cover tax liability.

Three months ended September 30, 2019

	Common stock		Additional Paid in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Stockholders' Equity
	Shares	Amount				
Balance at June 30, 2019	39,043	\$ 4	\$ 300,462	\$ 13	\$ (192,032)	\$ 108,447
Comprehensive loss						
Net loss	—	—	—	—	(15,293)	(15,293)
Change in unrealized gains on available for sale securities	—	—	—	5	—	5
Total comprehensive loss						(15,288)
Stock-based compensation expenses	—	—	1,826	—	—	1,826
Shares issued for consulting services	8	—	61	—	—	61
Exercise of common stock options	34	—	184	—	—	184
Balance at September 30, 2019	39,085	\$ 4	\$ 302,533	\$ 18	\$ (207,325)	\$ 95,230

Nine months ended September 30, 2020

	Common stock		Additional Paid in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Stockholders' Equity
	Shares	Amount				
Balance at December 31, 2019	39,204	\$ 4	\$ 304,963	\$ 13	\$ (223,059)	\$ 81,921
Comprehensive income						
Net loss	—	—	—	—	(10,898)	(10,898)
Change in unrealized gains on available for sale securities	—	—	—	11	—	11
Total comprehensive loss						(10,887)
Stock-based compensation expenses	—	—	6,081	—	—	6,081
RSU issuance of shares when vested ⁽³⁾	143	—	(617)	—	—	(617)
Shares withheld related to net shares settlement of equity awards ⁽⁴⁾	(34)	—	(249)	—	—	(249)
Exercise of common stock options	29	—	179	—	—	179
Common stock issued under ESPP	30	—	109	—	—	109
Balance at September 30, 2020	39,372	\$ 4	\$ 310,466	\$ 24	\$ (233,957)	\$ 76,537

(3)YTD Q3 2020, 238,696 RSU shares were vested, 142,948 shares were released, 95,748 shares were forfeited to cover tax liability.

(4)YTD Q3 2020, 87,500 RSA shares were vested, 53,541 shares were released, 33,959 shares were forfeited to cover tax liability.

Nine months ended September 30, 2019

	Common stock		Additional Paid in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Stockholders' Equity
	Shares	Amount				
Balance at December 31, 2018	33,948	\$ 3	\$ 252,885	\$ (11)	\$ (161,670)	\$ 91,207
Comprehensive loss						
Net loss	—	—	—	—	(45,655)	(45,655)
Change in unrealized gains on available for sale securities	—	—	—	29	—	29
Total comprehensive loss						(45,626)
Stock-based compensation expenses	—	—	5,588	—	—	5,588
RSU issuance of shares when vested ⁽⁵⁾	51	—	(279)	—	—	(279)
Shares withheld related to net shares settlement of equity awards ⁽⁶⁾	(21)	—	(214)	—	—	(214)
Shares issued for consulting services	8	—	61	—	—	61
Exercise of common stock options	215	—	1,116	—	—	1,116
Public offering of common stock, net of \$2,924 of offering costs	4,847	1	43,124	—	—	43,125
Common stock issued under ESPP	37	—	252	—	—	252
Balance at September 30, 2019	39,085	\$ 4	\$ 302,533	\$ 18	\$ (207,325)	\$ 95,230

(5) YTD Q3 2019, 78,750 RSU shares were vested, 51,212 shares were released, 27,538 shares were forfeited to cover tax liability.

(6) YTD Q3 2019, 62,500 RSA shares were vested, 40,938 shares were released, 21,562 shares were forfeited to cover tax liability.

9. Leases

Leases

We have non-cancelable operating leases for laboratory space in Burlingame, California with several amendments to expand the facility. In February 2020, we further amended non-cancelable operating leases for laboratory space in Burlingame, California for an expansion of an additional 2,260 square feet of laboratory space commencing on May 1, 2020 and expiring on May 31, 2025. The total non-cancellable operating lease for the entire existing laboratory space is 13,736 square feet, expiring May 31, 2025. In August 2015, we entered into a new non-cancelable operating lease for 3,126 square feet of office space in San Diego, California and in June 2019, renewed the lease through February 2025. Our headquarters office lease for 8,090 square feet of office space in Burlingame, California expires November 30, 2020. In September 2020, we renewed our headquarters for only 6,900 square feet of office space for another 3 years, expiring November 30, 2023. In April 2019, we signed a short-term lease in Burlingame ("April 2019 lease"), consisting of 1,979 square feet of space through April 2020. In May 2019, we signed another lease in Burlingame ("May 2019 lease"), consisting of 1,346 square feet of space through April 2022. In addition, we have five equipment leases expiring through 2027.

Operating lease expense was \$262,000 and \$793,000, respectively for the three and nine months ended September 30, 2020, which includes \$3,000 and \$5,000 short-term lease income, and none and \$28,000 of short-term lease expense for the three and nine months ended September 30, 2020, respectively. Operating lease expense was \$235,000 and \$704,000, respectively for the three and nine months ended September 30, 2019, which includes \$21,000 and \$78,000 of short-term lease expense, respectively. The following tables below do not include short term leases. We also have various equipment operating lease agreements.

Supplemental cash flow information, as of September 30, 2020, related to operating leases as follows (in thousands):

Amortization of operating lease	\$	600
Cash paid within operating cash flows	\$	668
Right-of-use assets obtained in exchange for new lease liabilities	\$	1,232

Supplemental balance sheet information, as of September 30, 2020, related to operating leases was as follows (in thousands, except lease term and discount rate):

Reported as:

Operating lease right-of-use assets	\$	3,634
Current portion of operating lease liabilities	\$	811
Long-term operating lease liabilities		3,147
Total lease liabilities	\$	<u>3,958</u>
Weighted average remaining lease term (years)		4.3 years
Weighted average discount rate		5.50%

As of September 30, 2020, we are obligated to make minimum lease payments under non-cancelable operating leases, as follows (in thousands):

Year ending December 31,	Lease Payments
2020 (remaining of year)	\$ 252
2021	1,012
2022	1,058
2023	1,047
2024	837
2025 and thereafter	258
Total lease payments	<u>4,464</u>
Less: imputed interest	(506)
Total lease liabilities	<u>\$ 3,958</u>

10. Commitments and contingencies

Purchase Commitments

In June 2018, we entered into a Strategic Supply Agreement (the “Agreement”), with Pall Corporation (“Pall”) for the purchase of equipment and consumables to be used in support of our manufacturing requirements, including, but not limited to the Plant. Pursuant to the agreement, we will purchase certain pharmaceutical manufacturing equipment and related services in the aggregate amount of \$3.8 million with a seven year consumable purchase obligation in the aggregate amount of approximately \$16.5 million. The agreement is subject to customary undertakings, covenants, obligations, rights and conditions. We have incurred \$3,778,000 in equipment purchase costs during the year ended of December 31, 2019. As of September 30, 2020, we are obligated to make consumable purchases and committed purchases as follows (in thousands):

Year ending December 31,	Consumable commitments		Consumable purchases		Remaining commitments	
2020	\$	1,650	\$	1,688	\$	(38)
2021		3,300		—		3,300
2022		3,625		—		3,625
2023		3,625		—		3,625
2024		4,285		—		4,285
Total	\$	16,485	\$	1,688	\$	14,797

11. Net Loss Per Share

Basic and diluted net loss per share was calculated as follows (in thousands, except per share amounts):

	Three months ended September 30,		Nine months ended September 30,	
	2020	2019	2020	2019
Basic and diluted net loss per share:				
Numerator:				
Net loss	\$ (12,183)	\$ (15,293)	\$ (10,898)	\$ (45,655)
Denominator:				
Weighted-average number of common shares outstanding, basic and diluted	39,312	38,940	39,246	38,542
Net loss per share, basic and diluted	\$ (0.31)	\$ (0.39)	\$ (0.28)	\$ (1.18)
Potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive:				
Options to purchase common stock	6,595	6,464	6,595	6,464
Unvested RSAs/RSUs	650	640	650	640
Total number of potentially issuable shares	7,245	7,104	7,245	7,104

There was no difference between the Company's net loss and the net loss attributable to common stockholders for all periods presented.

12. Restructuring plan

On March 16, 2020, we announced a strategic realignment of our business model whereby we plan to rely more on a partnership-based model for commercialization strategy similar to the traditional human biotech commercialization strategy whereby pipeline assets are partnered with larger commercial partners that can maximize product opportunity in return for upfront payments, contingent milestones, and royalties on future sales. Our focus will be on accelerating our deep pipeline of late-stage biologics candidates in canine and feline markets, while stopping small molecule development for these species. Accordingly, the companion animal commercial infrastructure will be substantially reduced. In connection with this restructuring, we eliminated 53 positions, representing about one-third of our workforce. The eliminated positions primarily relate to the companion animal sales force and research and development for small molecule programs. Restructuring expenses and retirement costs related to severance and health care benefits were approximately \$1.7 million, exclusive of stock compensation.

On June 8, 2020, we announced a plan to strengthen our strategic position by, among other things, prioritizing our most attractive late stage programs and substantially reducing our expenses to best position the Company for success with the previously announced business model. This restructuring reduced our workforce by approximately 24 employees and involved a restructuring charge of approximately \$2.3 million related to severance payments and health care benefits, exclusive of stock compensation. We further eliminated another 5 positions and incurred a restructuring charge of approximately \$0.3 million related to severance payments and health care benefits in the third quarter of 2020. We have completed our restructuring and do not anticipate any further reductions in our workforce for the foreseeable future.

13. Subsequent event

On April 8, 2020, we entered into an At Market Offering ("ATM") whereby we may offer and sell shares of our common stock from time to time up to \$25 million. In October 2020, 59,211 shares were sold through the ATM, for total gross proceeds of approximately \$298,000. Net proceeds, after deducting underwriting discounts and commissions and offering expense, were approximately \$186,000.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In this section, "KindredBio," "we," "our," "ours," "us" and the "Company" refer to Kindred Biosciences, Inc. and our wholly owned subsidiaries KindredBio Equine, Inc. and Centaur Biopharmaceutical Services, Inc. You should read the following discussion and analysis of our consolidated financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q consists of forward-looking statements such as statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates and statements regarding our anticipated revenues, expenses, margins, profits and use of cash. In this Quarterly Report on Form 10-Q, the words "anticipates," "believes," "expects," "intends," "future," "could," "estimates," "plans," "would," "should," "potential," "continues" and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances) often identify forward-looking statements.

These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our products and our product candidates for the foreseeable future; the likelihood that our revenue will vary from quarter to quarter; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our products and our lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our products and our product candidates and the potential inability of these manufacturers to deliver a sufficient amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on our business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to enter into satisfactory agreements with third-party licensees of our biologic products or to develop a satisfactory sales organization for our equine small molecule products; our significant costs of operating as a public company; potential cyber-attacks on our information technology systems or on our third-party providers' information technology systems, which could disrupt our operations; our potential inability to repay the secured indebtedness that we have incurred from third-party lenders, and the restrictions on our business activities that are contained in our loan agreement with these lenders; the risk that our 2020 strategic realignment and restructuring plans will result in unanticipated costs or revenue shortfalls; uncertainty about the amount of royalties that we will receive from the sale of Mirataz® to Dechra Pharmaceuticals PLC; the risk that the revenue from our delivery of services or products under any contract may be less than we anticipate if the other party to the contract exercises its right to terminate the contract prior to the completion of the contract; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.

For a further description of these risks and uncertainties and other risks and uncertainties that we face, please see the "Risk Factors" sections that are contained in our filings with the U.S. Securities and Exchange Commission (the "SEC"), including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 16, 2020, and any subsequent updates that may be contained in the "Risk Factors" sections of this Quarterly Report on Form 10-Q and our other Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks and uncertainties described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this Quarterly Report on Form 10-Q. Forward-looking statements contained in this Quarterly Report on Form 10-Q speak only as of the date of this report and we undertake no obligation to update or revise these statements, except as may be required by law.

Overview

We are a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Our mission is to bring to our pets the same kinds of safe and effective medicines that our human family members enjoy. Our core strategy is to identify compounds and targets that have already demonstrated safety and effectiveness in humans and to develop therapeutics based on these validated compounds and targets for pets, primarily dogs, cats and horses. We believe this approach will lead to shorter development times and higher approval rates than pursuing new, non-validated compounds and targets. Our current portfolio includes candidates in development consisting of primarily biologic pharmaceuticals.

Our first product, Mirataz® (mirtazapine transdermal ointment) was approved in May 2018 and became commercially available to veterinarians in the United States in July 2018. In November 2019, our second product, Zimeta™ (dipyron injection) for the control of fever in horses was approved by the FDA and became commercially available in December 2019. In addition, we have multiple other product candidates, including several biologics, in various stages of development.

On March 16, 2020, we entered into an Asset Purchase Agreement whereby we agreed to sell Mirataz, our transdermal drug for the management of weight loss in cats, to Dechra for a cash purchase price of \$43 million, of which \$38.7 million will be paid on the closing date and \$4.3 million will be paid out of escrow beginning in 12 months assuming no escrow claims, alongside an ongoing royalty on global net sales. The acquisition comprises worldwide marketing rights, intellectual property rights, marketing authorizations and associated regulatory documentation, third party supply contracts related to raw material and manufacture of the finished product, and certain product inventory. On April 15, 2020, we completed the sale of Mirataz to Dechra.

Concurrent with the sale of Mirataz, we announced a strategic realignment of our business model whereby we plan to rely more on a partnership-based model for commercialization strategy similar to the traditional human biotech commercialization strategy whereby pipeline assets are partnered with larger commercial partners that can maximize product opportunity in return for upfront payments, contingent milestones, and royalties on future sales. Our focus will be on accelerating our deep pipeline of late-stage biologics candidates in canine and feline markets, while stopping small molecule development for these species. We believe monoclonal antibodies are the future of veterinary medicine, and represent the greatest opportunity for value creation, given large potential markets for our programs and our competitive advantage in biologics. Accordingly, the companion animal commercial infrastructure will be substantially reduced. In connection with this restructuring, we eliminated 53 positions, representing about one-third of our workforce. The eliminated positions primarily relate to the companion animal sales force and research and development for small molecule programs. On June 8, 2020, we announced a second restructuring to eliminate an additional 24 positions to streamline our operations and reduce operating expenditures by prioritizing investment in our highest value, late stage programs, especially the interleukin-31 (IL-31) antibody, interleukin-4 receptor (IL-4R) antibody, and parvovirus antibody programs. We completed our restructuring by eliminating the last 5 remaining positions in the third quarter of 2020 and do not anticipate any further reductions in the foreseeable future.

Business and Development Updates

We recorded \$1.0 million and \$41.2 million in net revenues in the three and nine months ended September 30, 2020 compared with \$1.1 million and \$2.9 million for the same periods of 2019. Substantially all of the revenues recorded were due to the sale of our Mirataz asset in the second quarter of 2020. We continued selling Mirataz until April 15, 2020 when we completed the sale of Mirataz to Dechra, and in addition recorded Mirataz royalties in the second and third quarters of 2020. Revenues for Zimeta continue to be limited for the quarter as a result of COVID-19 and downturn in equine events and transportation.

On May 19, 2020, we entered into an agreement with Vaxart, Inc. for the manufacture of Vaxart's oral vaccine candidate for COVID-19. We recorded contract manufacturing revenue based on the percentage completion of specific milestones for the quarter. In October 2020, we announced the expansion of our manufacturing agreement with Vaxart for COVID-19 and other vaccine candidates.

Biologic Product Candidates

On October 30, 2018, we reported positive topline results from our pilot efficacy study of tirnovetmab, KIND-016, a fully caninized, high-affinity monoclonal antibody targeting interleukin-31 (IL-31), for the treatment of

atopic dermatitis in dogs. Following the successful pilot efficacy study, we conducted a pilot field effectiveness study for our IL-31 antibody and reported positive topline results on July 29, 2019. The manufacturing scale-up process proceeded as planned, and the pivotal efficacy study for KIND-016 is on track to start in the fourth quarter of 2020.

On March 24, 2020, we announced positive results from our pilot field efficacy study of KIND-025, a canine fusion protein targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of atopic dermatitis in dogs. A higher treatment success rate was observed in the KIND-025 group over the placebo group from week 1 through week 4. Positive efficacy signals were also detected with other endpoints including 20mm or higher reduction from baseline in PVAS score. Cell line development is being continued as we further evaluate this program. The IL-4 and IL-13 pathways are key drivers of the inflammation that underlies atopic dermatitis and other allergic diseases. The IL-4/13 SINK molecule binds to both IL-4 and IL-13 circulating in the blood and inhibits their interactions with their respective receptors, thereby modifying the clinical signs associated with atopic dermatitis. However, in line with our June 8 restructuring, we currently do not have plans to prioritize KIND-025 ahead of our other programs.

In December 2019, we announced the outcome of a positive pilot laboratory study of KIND-032, a fully caninized monoclonal antibody targeting interleukin-4 receptor, for the treatment of atopic dermatitis in dogs. The CADESI scores were assessed by board-certified veterinary dermatologists who were blinded to treatment assignments. The study demonstrated that KindredBio's antibody was well-tolerated. Although the study was a single-dose study designed primarily to assess safety and pharmacokinetics, evidence of positive efficacy and dose response was observed at Week 1, as measured by CADESI-04. A second pilot study to further assess dosing commenced in the third quarter of 2020. The KIND-032 program is advancing ahead of schedule and is being prioritized ahead of IL-4/13 SINK.

Atopic dermatitis is an immune-mediated inflammatory skin condition in dogs. It is the leading reason owners take their dog to the veterinarian, and the current market size is over \$700 million annually and growing rapidly. KindredBio is pursuing a multi-pronged approach toward atopic dermatitis, with a portfolio of promising biologics.

We announced positive results from our pilot efficacy study of KIND-030, a chimeric, high-affinity monoclonal antibody targeting canine parvovirus (CVP) in August 2019. On September 16, 2020, we reported positive results from our pivotal efficacy study of KIND-030 in prevention of parvovirus infection in prophylactic treatment. In the randomized, blinded, placebo-controlled study, KIND-030 was administered to dogs as prophylactic therapy to prevent clinical signs of CPV infection. The primary objectives of the study were met. All of the placebo-control dogs developed parvovirus infection as predefined in the study protocol, while none of the KIND-030 treated dogs developed the disease. Furthermore, the parvovirus challenge resulted in 60% mortality rate in the control dogs compared to 0% mortality rate in the KIND-030 treated dogs.

KIND-030 is being pursued for two indications in dogs: prophylactic therapy to prevent clinical signs of canine parvovirus infection and treatment of established parvovirus infection. The pivotal efficacy study for the treatment indication and pivotal safety study remain on track to be completed by year-end 2020, with approval expected by early 2021. Regulatory approval and review timeline are subject to the typical risks inherent in such a process.

CVP is the most significant contagious viral cause of enteritis in dogs, especially puppies, with mortality rates reportedly as high as 91%. There are currently no FDA or USDA approved treatments for CPV, nor any other available treatment.

The pivotal efficacy study for KindredBio's feline recombinant erythropoietin (KIND-510a) was initiated in the fourth quarter of 2019. Those veterinary clinics that had suspended clinical trials due to COVID-19 have since resumed operations. We continue to implement practices consistent with guidance provided by the U.S. Food and Drug Administration on studies conducted during the COVID-19 pandemic to minimize the impact on timelines. The product candidate is being developed for the management of non-regenerative anemia in cats. It has been engineered by the company to have a prolonged half-life compared to endogenous erythropoietin, a protein that regulates and stimulates production of red blood cells.

Anemia is a common condition that is estimated to afflict millions of older cats. It is often associated with chronic kidney disease, because kidneys produce erythropoietin and chronic kidney disease leads to decreased levels of endogenous erythropoietin. Chronic kidney disease affects approximately half of older cats, making it a leading cause of feline mortality. Human erythropoietins, which are multi-billion dollar products in the human market, have been shown to be immunogenic in many cats.

The pilot field effectiveness study for KIND-509, KindredBio's anti-TNF antibody for canine inflammatory bowel disease (IBD) is underway and on track to complete by year-end 2020. Those veterinary clinics that had suspended clinical trials due to COVID-19 have since resumed operations. KindredBio continues to implement practices consistent with guidance provided by the U.S. Food and Drug Administration on studies conducted during the COVID-19 pandemic to minimize the impact on timelines.

The majority of canine IBD cases involve chronic states of diarrhea, vomiting, gastroenteritis, inappetence, and other symptoms, certain of which are cited as among the most frequent disorders impacting dogs. For certain dog breeds, the prevalence of diarrhea exceeds 5%. Existing treatments can have significant drawbacks, including limited diets and excessive antibiotic use, which can lead to owner frustration, lapses in treatment adherence, or poor quality of life for the affected animal.

Equine Product Candidates

The pivotal field effectiveness study for KIND-012 (dipyron oral gel) for the treatment of fever in horses has been completed with positive results. The target animal safety study is also complete, and KIND-012 was found to be well-tolerated. KIND-012, which is a proprietary oral gel, is expected to expand use of the drug and build upon the success of Zimeta. We have agreed on a path forward with the FDA.

The pilot field effectiveness study of KIND-014 for the treatment of gastric ulcers in horses has been completed with positive results. The pivotal field efficacy study was initiated in the fourth quarter of 2019.

Equine gastric ulcer syndrome (EGUS) is a common condition in horses. Prevalence estimates have been reported to range from 60 to 90 percent in adult horses, depending on age, performance, and evaluated populations. A variety of clinical signs are associated with EGUS, including poor appetite, poor condition, colic, and behavioral issues.

Our strategic evaluation of the future of the equine franchise remains ongoing as a result of the strategic change we made in the second quarter of 2020 to discontinue small molecule development in favor of biologic programs..

Manufacturing

We have constructed a Good Manufacturing Practice, or GMP, biologics manufacturing plant in Burlingame, CA which is fully commissioned. We have proceeded to GMP manufacturing of our feline erythropoietin product candidate in January 2018. In addition, construction and commissioning of our biologics manufacturing lines in our manufacturing plant in Elwood, Kansas have also been completed. The Elwood facility includes approximately 180,000 square feet with clean rooms, utility, equipment, and related quality documentation suitable for biologics and small molecule manufacturing.

We are a commercial-stage company with two products approved for marketing and sale. On April 15, 2020, we completed the sale of one of the products, Mirataz, to Dechra. We have incurred significant net losses since our inception. We incurred cumulative net losses of \$233,957,000 through September 30, 2020. These losses have resulted principally from costs incurred in connection with investigating and developing our product candidates, research and development activities and general and administrative costs associated with our operations.

Historically, our funding has been a combination of private and public offerings. From our initial public offering in December 2013 through September 30, 2020, we raised approximately \$269.5 million in net proceeds, after deducting underwriting discounts and commissions and offering expenses. On April 8, 2020, we entered into an at the market offering agreement where we may offer and sell from time to time shares of our common stock, having an aggregate offering price of up to \$25.0 million.

On September 30, 2019, we entered into the Loan Agreement with the Lenders. The Loan Agreement provides KindredBio with up to \$50 million of borrowing capacity available in three tranches, each bearing interest at 1-Month LIBOR + 6.75% with a floor of 2.17%. Under the terms of the agreement, an initial tranche of \$20 million was funded at closing. KindredBio is required to make interest only payments on a monthly basis through October 2021. An additional \$30 million will be available in two tranches at our option, subject to certain conditions. The entire debt facility will mature on September 30, 2024. See Note 6 to our condensed consolidated financial statements for further details.

As of September 30, 2020, we had cash, cash equivalents and investments of \$66,837,000. Our sale of Mirataz to Dechra was completed on April 15, 2020 with proceeds of \$38.7 million received and the balance of \$4.3 million to be paid out from escrow beginning in 12 months assuming no escrow claims.

For the foreseeable future, we expect to continue to incur losses as we continue our product development activities, seek regulatory approvals for our product candidates and begin to commercialize or partner them if they are approved by the Center for Veterinary Medicine branch, or CVM, of the FDA, the U.S. Department of Agriculture, or USDA, or the European Medicines Agency, or EMA. If we are required to further fund our operations, we expect to do so through public or private equity offerings, debt financings, corporate collaborations and licensing arrangements. We cannot assure you that such funds will be available on terms favorable to us, if at all. The strategic realignment of our business model whereby we rely more on a partnership-based model for commercialization strategy similar to the traditional human biotech commercialization strategy whereby pipeline assets are partnered with larger commercial partners that can maximize product opportunity in return for upfront payments, contingent milestones, and royalties on future sales may require us to relinquish rights to certain of our technologies. In addition, we may never successfully complete development of, obtain adequate patent protection for, obtain necessary regulatory approval, or achieve commercial viability for any other product candidates besides Mirataz and Zimeta. If we are not able to raise additional capital on terms acceptable to us, or at all, as and when needed, we may be required to curtail our operations, and we may be unable to continue as a going concern.

Critical Accounting Policies and Significant Judgments and Estimates

Our management's discussion and analysis of financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and revenue, costs and expenses and related disclosures during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Beginning with the second quarter of 2020, we included revenue from asset sale, partner royalties and contract manufacturing revenue (see Note 1 to our financial statements) as significant accounting policies. There have been no other significant changes to our critical accounting policies since the beginning of our fiscal year. Our critical accounting policies are described in the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 16, 2020.

Results of Operations

In March 2020, we announced a strategic realignment of our business model whereby we plan to rely more on a partnership-based model for commercialization strategy similar to the traditional human biotech commercialization strategy whereby pipeline assets are partnered with larger commercial partners that can maximize product opportunity in return for upfront payments, contingent milestones, and royalties on future sales. Our focus will be on accelerating our deep pipeline of late-stage biologics candidates in canine and feline markets, while stopping small molecule development for these species. We believe monoclonal antibodies are the future of veterinary medicine, and represent the greatest opportunity for value creation, given large potential markets for our programs and our competitive advantage in biologics. In connection with this restructuring, we eliminated 53 positions, representing about one-third of our workforce. The eliminated positions primarily relate to the companion animal sales force and research and development for small molecule programs. Restructuring expenses and retirement costs related to severance and health care benefits were approximately \$1.7 million, exclusive of stock compensation.

On June 8, 2020, we announced a plan to strengthen our strategic position by, among other things, prioritizing our most attractive late stage programs and substantially reducing our expenses to best position the company for success with the previously announced business model. This restructuring reduced the company's workforce by approximately 24 employees and involved a restructuring charge of approximately \$2.3 million related to severance payments and health care benefits, exclusive of stock compensation. We further eliminated another 5 positions and incurred a restructuring charge of approximately \$0.3 million related to severance payments and health care benefits in the third quarter of 2020. We have completed our restructuring and do not expect any further reductions in our workforce for the foreseeable future.

The following table summarizes the results of our operations for the periods indicated (in thousands):

	Three months ended September 30,		Nine months ended September 30,	
	2020	2019	2020	2019
Revenues:				
Net product revenues	\$ 16	\$ 1,104	\$ 782	\$ 2,855
Revenue from asset sale	—	—	38,700	—
Partner royalty revenue	255	—	413	—
Contract manufacturing revenue	772	—	1,318	—
Total revenues	1,043	1,104	41,213	2,855
Operating costs and expenses:				
Cost of product revenues ⁽¹⁾	5	139	3,609	400
Contract manufacturing costs	300	—	636	—
Research and development	7,387	7,290	23,652	21,176
Selling, general and administrative	4,698	9,382	18,676	28,348
Restructuring costs	282	—	4,246	—
Total operating costs and expenses	12,672	16,811	50,819	49,924
Loss from operations	(11,629)	(15,707)	(9,606)	(47,069)
Interest and other income (expenses), net	(554)	414	(1,292)	1,414
Net loss	\$ (12,183)	\$ (15,293)	\$ (10,898)	\$ (45,655)

(1) Includes \$3,494,000 Finished Goods write-off in the first quarter of 2020 related to the Dechra Asset Purchase Agreement, due to the transition to proprietary Dechra brand labelling on asset sale.

Revenues

We recorded \$1.0 million and \$41.2 million in net revenues in the three and nine months ended September 30, 2020 compared with \$1.1 million and \$2.9 million for the same periods of 2019. The increase in revenue was primarily

due to \$38.7 million from the sale of our Mirataz asset which was completed on April 15, 2020. In addition, royalty revenues of \$255,000 and \$413,000, and contract manufacturing revenues of \$772,000 and \$1,318,000 for the three and nine months in 2020 contributed to the increase.

Of the \$782,000 net product revenues recorded in the first nine months of 2020, \$734,000 were for Mirataz. There were no Mirataz revenues for the quarter ended September 30, 2020 as a result of the asset sale. Net product revenues for Zimeta were \$4,000 and \$19,000 for three and nine months ended September 30, 2020, reflecting a downturn in equine events and transportation as a result of COVID-19. In conjunction with Mirataz and Zimeta, we also recorded \$12,000 and \$29,000 in revenue derived from co-marketing products for our partners, Butterfly Networks and Astaria Global for the same periods in 2020.

On May 19, 2020, we entered into an agreement with Vaxart, Inc. for the manufacture of Vaxart's oral vaccine candidate for COVID-19. We recorded contract manufacturing revenue of \$772,000 and \$1,318,000 based on the percentage completion of specific milestones for the three and nine months ended September 30, 2020, respectively.

Our net product revenue was generated entirely from sales within the United States. Our product sales to two large distributors, namely Covetrus and Midwest Veterinary Supply, and three large distributors, namely MWI Animal Health, Covetrus and Midwest Veterinary Supply, each accounted for more than 10% of gross product revenues for the three and nine months ended September 30, 2020. Approximately 100% and 75% of our gross product revenues were to two and three distributors for the three and nine months ended September 30, 2020, respectively. Three distributors attributed to approximately 84% and 85% of our gross product revenues for the three and nine months ended September 30, 2019, respectively.

Our accounts receivable from amounts billed for contract manufacturing services is derived from one customer. The contract requires an up-front payment and installment payments during the service period. We perform periodic evaluations of the financial condition of our customers and generally do not require collateral, but we can terminate any contract if a material default occurs.

We currently estimate a 3% product return liability for Zimeta, using probability-weighted available industry data and data provided by our distributors such as the inventories remaining in the distribution channel (see Notes 1 and 2 to our financial statements). Previous product liability accrued for Mirataz will be re-assessed prior to the end of 2020 to determine if such liability is still necessary. To-date we did not have any product returns. We did not record an allowance for doubtful accounts as our analysis did not uncover any collection risks.

Cost of Product Revenues

Cost of product revenues consists primarily of the cost of direct materials, direct labor and overhead costs associated with manufacturing, inbound shipping and other third-party logistics costs.

As a result of the sale of Mirataz, we determined that the remaining Mirataz product not included in the sale of transferred assets to Dechra did not have any future use. Accordingly, we wrote-off approximately \$3,494,000 Mirataz inventory upon the signing of the Asset Purchase Agreement on March 16, 2020, due to the transition to proprietary Dechra brand labelling.

Contract Manufacturing Costs

Contract manufacturing costs consist primarily of the cost of direct materials, direct labor and overhead costs associated with manufacturing, rent, facility costs and related machinery depreciation.

Research and Development Expense

All costs of research and development are expensed in the period incurred. Research and development costs consist primarily of salaries and related expenses for personnel, stock-based compensation expense, fees paid to consultants, outside service providers, professional services, travel costs and materials used in clinical trials and research and development. We typically use our employee and infrastructure resources across multiple development programs.

Research and development expense was as follows for the periods indicated (in thousands, except for percentages):

	Three months ended September 30,		% Change	Nine months ended September 30,		% Change
	2020	2019		2020	2019	
Payroll and related	\$ 2,108	\$ 2,954	(29)%	\$ 8,730	\$ 9,309	(6)%
Consulting	203	627	(68)%	579	2,147	(73)%
Field trial costs, including materials	472	1,559	(70)%	2,108	2,967	(29)%
Biologics development and supplies	2,409	608	296%	5,200	2,077	150%
Stock-based compensation	434	475	(9)%	1,496	1,408	6%
Other	1,761	1,067	65%	5,539	3,268	69%
	<u>\$ 7,387</u>	<u>\$ 7,290</u>	1%	<u>\$ 23,652</u>	<u>\$ 21,176</u>	12%

During the three and nine months ended September 30, 2020, research and development expense related primarily to advancing the development of KIND-030, KIND-016, KIND-032, KIND-510a and other early stage biologic programs.

Research and development expenses for the three months ended September 30, 2020, increased by 1% to \$7,387,000 compared with \$7,290,000 for the same period in 2019. The \$97,000 increase was primarily due to the inclusion of expenses from the Kansas facility as it began to manufacture clinical trial material offset by lower costs as we stopped small molecule development and prioritize our focus on late stage biologic candidates. Prior to 2020, construction and commissioning expenditures associated with the Kansas facility had been categorized as general and administrative expenses. Outsourced research and development expenses related to KIND-510a, KIND-014 and other product development programs for three months ended September 30, 2020 were \$447,000, \$73,000, and \$46,000, respectively. Outsourced research and development expense consists primarily of costs related to CMC, clinical trial costs and consulting.

Research and development expenses for the nine months ended September 30, 2020, increased by 12% to \$23,652,000 compared with \$21,176,000 for the same period in 2019. The \$2,476,000 increase was primarily due to the inclusion of expenses from the Kansas facility as it began to manufacture clinical trial material offset by lower costs as we stopped small molecule development and prioritize our focus on late stage biologic candidates. Prior to 2020, construction and commissioning expenditures associated with the Kansas facility had been categorized as general and administrative expenses. Outsourced research and development expenses related to KIND-510a, KIND-014, and other product development programs for nine months ended September 30, 2020 were \$1,000,000, \$405,000, \$795,000, respectively. Outsourced research and development expense consists primarily of costs related to CMC, clinical trial costs and consulting.

We expect research and development expense to decrease for the rest of the year due to our restructuring and prioritizing our most attractive late stage programs to reduce our expenses to best position the company for success. Due to the inherently unpredictable nature of our development, we cannot reasonably estimate or predict the nature, specific timing or estimated costs of the efforts that will be necessary to complete the development of our product candidates.

Selling, General and Administrative Expense

Selling, general and administrative expense was as follows for the periods indicated (in thousands, except for percentages):

	Three months ended September 30,			%	Nine months ended September 30,			%
	2020	2019	Change		2020	2019	Change	
Payroll and related	\$ 1,072	\$ 3,557	(70)%	\$ 5,590	\$ 11,415	(51)%		
Consulting, legal and professional services	1,014	905	12%	3,550	2,493	42%		
Stock-based compensation	1,660	1,351	23%	4,585	4,180	10%		
Corporate and marketing expenses	419	1,178	(64)%	2,295	3,953	(42)%		
Other	533	2,391	(78)%	2,656	6,307	(58)%		
	<u>\$ 4,698</u>	<u>\$ 9,382</u>	<u>(50)%</u>	<u>\$ 18,676</u>	<u>\$ 28,348</u>	<u>(34)%</u>		

Selling, general and administrative expenses for the three and nine months ended September 30, 2020 decreased by 50% to \$4,698,000 and 34% to \$18,676,000, when compared to the same periods in 2019. The \$9,672,000 year-over-year decrease was mainly due to the re-categorization of Kansas plant expenditures as research and development expenses and lower payroll and related expenses as a result of the elimination of our companion animal sales force, offset by higher legal fees.

We expect selling, general and administrative expense to decrease going forward due to the restructuring and elimination of our companion animal sales force. We plan to rely more on a partnership-based model for commercialization whereby our pipeline assets are partnered with larger commercial partners that can maximize product opportunity in return for upfront payments, contingent milestones, and royalties on future sales.

Restructuring costs

We recorded restructuring charges of \$0.3 million and \$4.2 million for three and nine months ended September 30, 2020. The restructuring charge of \$1.7 million in the first quarter of 2020 was the result of the elimination of 53 positions due to the strategic realignment of our business model whereby we became a biologics-only company while stopping small molecule development. All charges pertaining to this restructuring have been paid. The restructuring charge of \$2.3 million in the second quarter was the result of prioritizing our most attractive late stage programs and substantially reducing our expenses to best position the company for success with the new business model. Another 24 employees were impacted by the restructuring and all restructuring charges have been paid by the third quarter of 2020. We further eliminated another 5 positions in the third quarter and incurred a restructuring charge of approximately \$0.3 million related to severance payments and health care benefits, exclusive of stock compensation. We do not anticipate any further reductions in the foreseeable future.

Interest and Other Income, Net

(In thousands)

	Three months ended September 30,			Change	Nine months ended September 30,			Change
	2020	2019	Change		2020	2019	Change	
Interest and other (expense) income, net	\$ (554)	\$ 414	\$ (968)	\$ (1,292)	\$ 1,414	\$ (2,706)		

The decrease of approximately \$968,000 in the three months ended September 30, 2020 compared to the same period in 2019 was the result of \$359,000 lower interest income due to lower interest rate and cash balance. In addition, the change was further impacted by interest expense of approximately \$451,000 and other loan amendment and amortization fees of approximately \$88,000. There were no borrowing expenses in the same quarter of 2019.

The decrease of approximately \$2,706,000 in the nine months ended September 30, 2020 compared to the same period in 2019 was the result of \$1,044,000 lower interest income due to lower interest rate and cash balance. In

addition, the change was further impacted by interest expense of approximately \$1,351,000, and other loan amendment and amortization fees of approximately \$375,000. There were no borrowing expenses in the same periods of 2019.

Income Taxes

We have historically incurred operating losses and maintain a full valuation allowance against our net deferred tax assets. Our management has evaluated the factors bearing upon the realizability of our deferred tax assets, which are comprised principally of net operating loss carryforwards and concluded that, due to the uncertainty of realizing any tax benefits as of September 30, 2020, a valuation allowance was necessary to fully offset our deferred tax assets.

Liquidity and Capital Resources

We have incurred losses and negative cash flows from operations since our inception in September 2012 through September 30, 2020. As of September 30, 2020, we had an accumulated deficit of \$234.0 million. Since inception and through September 30, 2020, we raised approximately \$269.5 million in net proceeds. On September 30, 2019, we entered into the Loan Agreement with the Lenders. The Lenders have agreed to make available to us an aggregate principal amount of up to \$50.0 million under the Loan Agreement. On September 30, 2019, we received the first loan tranche of \$19.2 million, net of debt issuance costs. An additional \$30 million will be available in two tranches at our option, subject to certain conditions.

As of September 30, 2020, we had cash, cash equivalents and investments of \$66.8 million. We believe that our cash, cash equivalents and investments along with the net reduction in our workforce, remaining proceeds from the Mirataz sale, and revenues from royalties and contract manufacturing will be sufficient to fund our planned operations through mid-2022. In addition, the potential additional draw down of \$30 million from our Loan Agreement, which is contingent on the achievement of certain milestones, and our April 8, 2020 ATM facility will provide us with access to additional cash and extend our runway, if required.

Cash Flows

The following table summarizes our cash flows for the periods set forth below:

	Nine months ended September 30,	
	2020	2019
	(In thousands)	
Net cash used in operating activities	\$ (3,297)	\$ (42,647)
Net cash provided by (used in) investing activities	\$ 4,503	\$ (37,680)
Net cash (used in) provided by financing activities	\$ (578)	\$ 63,189

Net cash used in operating activities

During the nine months ended September 30, 2020, net cash used in operating activities was \$3,297,000. The net loss of \$10,898,000 for the nine months ended September 30, 2020 included non-cash charges of \$6,081,000 for stock-based compensation expense, \$3,473,000 for depreciation and amortization, \$259,000 for amortization of the debt discount of long-term loan, \$3,494,000 for Mirataz finished goods write-off related to Dechra asset purchase, \$54,000 loss on disposal of property and equipment, and partially offset by \$113,000 for the amortization of discount on marketable securities. Net cash used in operating activities was further increased by net changes in operating assets and liabilities of \$5,647,000.

During the nine months ended September 30, 2019, net cash used in operating activities was \$42,647,000. The net loss of \$45,655,000 for the nine months ended September 30, 2019 included non-cash charges of \$5,588,000 for stock-based compensation expenses, \$61,000 for shares issued for consulting services, \$1,761,000 for depreciation and amortization, \$134,000 loss on disposal of property and equipment, and partially offset by \$419,000 for the amortization of premium on marketable securities. Net cash used in operating activities was further increased by net changes in operating assets and liabilities of \$4,117,000.

Net cash provided by (used in) investing activities

During the nine months ended September 30, 2020, net cash provided by investing activities was \$4,503,000, which resulted from proceeds from maturities of marketable securities of \$77,520,000, offset by \$70,059,000 related to purchases of marketable securities and \$3,040,000 related to purchases of equipment. In addition, we also received proceeds of \$82,000 from the sale of equipment.

During the nine months ended September 30, 2019, net cash used in investing activities was \$37,680,000, due to proceeds from maturities of marketable securities of \$55,678,000 and sales of investments of \$2,999,000, offset by the purchases of marketable securities of \$89,079,000 and purchases of property and equipment of \$7,281,000. In addition, we also received proceeds of \$3,000 from the sale of equipment.

Net cash (used in) provided by financing activities

During the nine months ended September 30, 2020, net cash used in financing activities of \$578,000 was related to payment of \$866,000 related to restricted stock awards and restricted stock units tax liability on net settlement, offset by proceeds of \$288,000 from exercises of stock options and purchase of ESPP shares.

During the nine months ended September 30, 2019, net cash provided by financing activities of \$63,189,000 was related to net proceeds of \$43,125,000 from the sale of common stock from a public offering, net proceeds of \$19,189,000 from the loan payable, proceeds of \$1,368,000 from the purchases of common stock through exercise of stock options and purchase of ESPP shares, offset by payment of \$493,000 related to restricted stock awards tax liability on net settlement.

Future Funding Requirements

We anticipate that we will continue to incur losses for the next several years due to expenses relating to:

- pivotal trials of our product candidates;
- toxicology (target animal safety) studies for our product candidates;
- biologic clinical material manufacturing; and
- maintain the operations of the biologics manufacturing plant in Kansas.

We believe that our cash, cash equivalents and investments along with the net reduction in our workforce, remaining proceeds from the Mirataz sale, and revenues from royalties and contract manufacturing will be sufficient to fund our planned operations through mid-2022. In addition, the potential additional draw down of \$30 million from our Loan Agreement, which is contingent on the achievement of certain milestones, and our April 8, 2020 ATM facility will provide us with access to additional cash and extend our runway, if required. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. Such financing may result in dilution to stockholders, imposition of debt covenants and repayment obligations or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.

Our future capital requirements depend on many factors, including, but not limited to:

- the scope, progress, results and costs of researching and developing our current or future product candidates;
- the timing of, and the costs involved in, obtaining regulatory approvals for any of our current or future product candidates;
- the number and characteristics of the product candidates we pursue;
- the cost of manufacturing our current and future product candidates and any products we successfully commercialize, including the cost of internal biologics manufacturing capacity;
- the cost of commercialization activities if any of our current or future product candidates are approved for sale, including marketing, sales and distribution costs;
- the expenses needed to attract and retain skilled personnel;
- the costs associated with being a public company;

- our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements; and
- the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation costs and the outcome of any such litigation.

Since inception, we have not engaged in the use of any off-balance sheet arrangements, such as structured finance entities, special purpose entities or variable interest entities.

Contractual Obligations

We have non-cancelable operating leases for laboratory space in Burlingame, California with several amendments to expand the facility. In February 2020, we further amended non-cancelable operating leases for laboratory space in Burlingame, California for an expansion of an additional 2,260 square feet of laboratory space commencing on May 1, 2020 and expiring on May 31, 2025. The total non-cancellable operating lease for the entire existing laboratory space is 13,736 square feet, expiring May 31, 2025. In August 2015, we entered into a new non-cancelable operating lease for 3,126 square feet of office space in San Diego, California and in June 2019, renewed the lease through February 2025. Our headquarters office lease for 8,090 square feet of office space in Burlingame, California expires November 30, 2020. In September 2020, we renewed our headquarters for only 6,900 square feet of office space for another 3 years, expiring November 30, 2023. In April 2019, we signed a short-term lease in Burlingame ("April 2019 lease"), consisting of 1,979 square feet of space through April 2020. In May 2019, we signed another lease in Burlingame ("May 2019 lease"), consisting of 1,346 square feet of space through April 2022. In addition, we have five equipment leases expiring through 2027.

Under the operating leases we are obligated to make minimum lease payments as of September 30, 2020 totaling \$4,464,000 through August 2027, the timing of which is described in more detail in the notes to the condensed consolidated financial statements.

Off-Balance Sheet Arrangements

As of September 30, 2020, we did not have any material off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of SEC Regulation S-K.

Recently Issued Accounting Pronouncements

In March 2020, the FASB issued ASU No. 2020-04, "Reference Rate Reform (Topic 848)", changes to the interbank offered rates (IBORs), and, particularly, the risk of cessation of the London Interbank Offered Rate (LIBOR). The amendments provide optional expedients and exceptions for applying U.S. GAAP to contracts that reference LIBOR expected to be discontinued because of reference rate reform. The expedients and exceptions do not apply to contract modifications made after December 31, 2022. The following optional expedients are permitted for contracts that are modified because of reference rate reform and that meet certain scope guidance: Modifications of contracts within the scope of Topics 470, Debt, should be accounted for by prospectively adjusting the effective interest rate. The amendments also permit an entity to consider contract modifications due to reference rate reform to be an event that does not require contract remeasurement at the modification date or reassessment of a previous accounting determination. When elected, the optional expedients for contract modifications must be applied consistently for all contracts. It applies to all entities within the scope of the affected accounting guidance and will take effect as of March 12, 2020 through December 31, 2022. We have one loan contract which references LIBOR rate. We have not modified the contract with our lenders yet. We are currently evaluating the new guidance and have not determined the impact this standard may have on our financial statements.

We do not believe there are any other recently issued standards not yet effective that will have a material impact on our financial statements when the standards become effective.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The primary objective of our investment activities is to preserve capital. We do not utilize hedging contracts or similar instruments.

We are exposed to certain market risks relating primarily to (1) interest rate risk on our cash and cash equivalents, (2) market price risk on our investments, and (3) risks relating to the financial viability of the institutions which hold our capital and through which we have invested our funds. We manage such risks by investing in short-term, liquid, highly-rated instruments. As of September 30, 2020, our cash equivalents and investments are invested in money market funds, U.S. treasury bills, U.S. federal agency notes, corporate notes, commercial paper and U.S treasury bonds. We do not believe we have any material exposure to interest rate risk due to the extremely low interest rate environment, the short duration of the securities we hold and our ability to hold our investments to maturity if necessary. Declines in interest rates would reduce investment income, but would not have a material effect on our financial condition or results of operations.

We do not currently have exposure to foreign currency risk.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

As of the end of the period covered by this quarterly report on Form 10-Q, our management, with the participation of our Chief Executive Officer and Chief Financial Officer (the “Certifying Officers”), evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the “Exchange Act”), such as this report, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure. Based on these evaluations, the Certifying Officers have concluded, that, as of the end of the period covered by this report:

(a) our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms; and

(b) our disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Exchange Act was accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There has not been any change in our internal control over financial reporting that occurred during the period ended September 30, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

You should consider the “Risk Factors” included under Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 16, 2020. There have been no material changes to those Risk Factors.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS**EXHIBIT INDEX**

Exhibit Number	Description
10.1	Severance and Release Agreement dated as of July 31, 2020 between Kindred Biosciences, Inc. and Denise Bevers (previously filed by Kindred Biosciences, Inc. with the Securities and Exchange Commission on August 5, 2020 as Exhibit 10.1 to the company's Current Report on Form 8-K and incorporated herein by reference)
31.1	Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer
31.2	Sarbanes-Oxley Act Section 302 Certification of Chief Financial Officer
32.1	Sarbanes-Oxley Act Section 906 Certification of Chief Executive Officer and Chief Financial Officer
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 9, 2020

Kindred Biosciences, Inc.

By: /s/ Wendy Wee
Wendy Wee
Chief Financial Officer
(Principal Financial and
Accounting Officer)

Certification of the Chief Executive Officer Under Section 302 of the Sarbanes-Oxley Act

I, Richard Chin, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Kindred Biosciences, Inc.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d- 15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2020

By: /s/ Richard Chin

Name: Richard Chin, MD

Title: Chief Executive Officer

(Principal Executive Officer)

Certification of the Chief Financial Officer Under Section 302 of the Sarbanes-Oxley Act

I, Wendy Wee, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Kindred Biosciences, Inc.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d- 15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2020

By: /s/ Wendy Wee

Name: Wendy Wee

Title: Chief Financial Officer

(Principal Financial and Accounting
Officer)

**CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER**

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Kindred Biosciences, Inc. (the “Company”) hereby certifies that, to his or her knowledge:

- (i) The quarterly report on Form 10-Q for the period ended September 30, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
- (ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 9, 2020

By: /s/ Richard Chin

Name: Richard Chin, MD
Title: Chief Executive Officer
(Principal Executive Officer)

By: /s/ Wendy Wee

Name: Wendy Wee
Title: Chief Financial Officer
(Principal Financial and Accounting Officer)